- Home
- VKTX vs RARE Comparison
VKTX vs RARE Comparison
Compare VKTX & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- RARE
- Stock Information
- Founded
- VKTX 2012
- RARE 2010
- Country
- VKTX United States
- RARE United States
- Employees
- VKTX N/A
- RARE N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- RARE Health Care
- Exchange
- VKTX Nasdaq
- RARE Nasdaq
- Market Cap
- VKTX 3.8B
- RARE 3.2B
- IPO Year
- VKTX 2015
- RARE 2014
- Fundamental
- Price
- VKTX $35.22
- RARE $34.59
- Analyst Decision
- VKTX Strong Buy
- RARE Strong Buy
- Analyst Count
- VKTX 14
- RARE 13
- Target Price
- VKTX $87.00
- RARE $87.69
- AVG Volume (30 Days)
- VKTX 4.8M
- RARE 1.3M
- Earning Date
- VKTX 10-22-2025
- RARE 11-04-2025
- Dividend Yield
- VKTX N/A
- RARE N/A
- EPS Growth
- VKTX N/A
- RARE N/A
- EPS
- VKTX N/A
- RARE N/A
- Revenue
- VKTX N/A
- RARE $610,159,000.00
- Revenue This Year
- VKTX N/A
- RARE $19.65
- Revenue Next Year
- VKTX N/A
- RARE $23.35
- P/E Ratio
- VKTX N/A
- RARE N/A
- Revenue Growth
- VKTX N/A
- RARE 26.77
- 52 Week Low
- VKTX $18.92
- RARE $25.81
- 52 Week High
- VKTX $79.10
- RARE $53.48
- Technical
- Relative Strength Index (RSI)
- VKTX 60.22
- RARE 61.20
- Support Level
- VKTX $33.00
- RARE $33.02
- Resistance Level
- VKTX $36.11
- RARE $35.95
- Average True Range (ATR)
- VKTX 2.02
- RARE 1.30
- MACD
- VKTX 0.09
- RARE 0.16
- Stochastic Oscillator
- VKTX 73.40
- RARE 72.80
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.